Engflag

Maxigra ODT

Quick links to important sections

Maxigra ODT

Maxigra ODT_EN

Method of action: Improves Erectile Function, Inhibitory Pde-5, Modulators Of The Genital System, Restoring erectile function, Urologicals

Treatment option: Impotence, Heart Disease, Congenital Heart Disease, Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Sexual Dysfunction, Male

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxigra ODT

Maxigra ODT is a specific pharmaceutical preparation containing the active ingredient Sildenafil (specifically as Sildenafil citrate), a synthetic compound. The medication is officially classified as a Selective Phosphodiesterase type 5 (PDE5) Inhibitor, defining its fundamental therapeutic mechanism within the body.

Quick Facts

Property Description
Active ingredient Sildenafil (as citrate salt)
Form Orally Disintegrating Tablet (ODT)
Pharmacological class Selective PDE5 Inhibitor
General purpose Assisting with Erectile Dysfunction
Origin Synthetic Compound

What Type of Medicine is Maxigra ODT and Its Active Agent?

Maxigra ODT is a medicinal product defined by its active agent, Sildenafil, a synthetic compound used in the treatment of human disease. The core identity of the medicine is its pharmacological class: it is a Selective Phosphodiesterase type 5 (PDE5) Inhibitor. This classification indicates the drug targets a specific enzyme (PDE5) to affect vascular dynamics. As a single-ingredient product, its therapeutic action is solely attributable to Sildenafil, which is chemically engineered for targeted function. The effectiveness of Sildenafil in its primary use is clinically recognized and supported by extensive pharmacological studies.

What is Unique About the Orally Disintegrating Tablet (ODT) Form?

The distinguishing characteristic of the preparation is its Orally Disintegrating Tablet (ODT) dosage form, a specialized solid oral preparation designed for rapid disintegration. An ODT is engineered to break down quickly into a fine suspension upon contact with saliva in the mouth, often without the need for additional water. This specific oral disintegrating tablet formulation utilizes specific solid excipients to achieve immediate breakdown. The ODT form provides a convenient alternative method of oral administration for adult men, particularly those who find swallowing conventional tablets challenging, facilitating ease of use as an on-demand treatment.

What is the General Purpose of Sildenafil in Maxigra ODT?

The general purpose of the Sildenafil found in Maxigra ODT is to assist adult men experiencing Erectile Dysfunction (ED) or Sexual impotence. The drug’s action as a PDE5 inhibitor results in vasodilatory properties, ultimately supporting an increase in blood flow to the penis following sexual stimulation. By modulating the key enzyme, the medication helps facilitate the body's natural physical response required for the patient to achieve or maintain an erection.

Regulatory References

  1. National Library of Medicine (NIH)
  2. MedlinePlus

What side effects are possible with Maxigra ODT?

Possible Side Effects and Safety Information

The safety profile of Sildenafil, the active ingredient in Maxigra ODT, is formally classified by government regulatory authorities according to the frequency and physiological system affected.

Adverse Reaction Classifications

Side effects are categorized by how often they are expected to occur:

  • Very Common (Affecting >1 in 10): The most frequently documented adverse reaction is Headache.
  • Common (Affecting up to 1 in 10): These include Flushing (reddening of the face), Dizziness, Nasal congestion, Dyspepsia (indigestion), Nausea, and common Visual disturbances (such as blurred or color-tinged vision).
  • Uncommon/Rare: Less frequent effects are documented across various systems, including Tachycardia (increased heart rate), Hypotension (low blood pressure), Rash, and Vomiting.

Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but serious adverse events that have been associated with Sildenafil use. These include Priapism (a prolonged erection lasting over four hours), Sudden decrease or loss of hearing, and serious Cardiovascular events (e.g., myocardial infarction, stroke). Non-arteritic anterior ischaemic optic neuropathy (NAION), a cause of sudden vision loss, is also documented as a rare safety concern.

Safety Restrictions (Contraindications): The use of Sildenafil is strictly contraindicated in patients who are simultaneously taking any form of organic nitrates due to the risk of severe hypotension. Contraindications also apply to individuals with severe hepatic impairment, recent stroke or myocardial infarction, or a history of vision loss due to NAION.

Population Considerations: Regulatory notes confirm that reduced drug clearance is a documented safety factor for patients with severe renal or hepatic impairment and that increased plasma concentrations are observed in older adults (65 years and over).

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Maxigra ODT (Sildenafil) is primarily characterized by an exaggeration of the drug’s known effects, resulting in the occurrence of typical adverse events at a higher incidence and severity. In clinical studies, healthy volunteers given doses up to 800 mg experienced adverse events similar to those seen at lower therapeutic doses, but with an increased frequency.

Documented Overdose Symptoms

Overdose presentations typically include an increase in the frequency and intensity of symptoms related to the drug's vasodilatory action, such as:

  • Headache
  • Flushing (reddening of the face and neck)
  • Dizziness
  • Dyspepsia (indigestion)
  • Visual disturbances

Emergency Actions and Urgent Medical Help

In the event of an overdose, standard supportive measures should be adopted as required to manage symptoms. It is important to note that because Sildenafil is highly bound to plasma proteins, procedures like renal dialysis are not expected to accelerate clearance from the body.

Immediate medical attention is required if a severe adverse event occurs or if a prolonged erection (priapism) lasts for more than 4 hours. Priapism is a medical emergency that can cause permanent tissue damage if not treated promptly.

Therapeutic Uses of Maxigra ODT

Maxigra ODT is indicated for the management of symptoms associated with erectile dysfunction (ED) in adult men. This condition is characterized by an inability to achieve or maintain a penile erection adequate for satisfactory sexual performance. The therapeutic purpose of this medication is to support the natural response to sexual stimulation.

Approved clinical scenarios of use focus on providing symptomatic relief for individuals diagnosed with this form of sexual dysfunction. Utilizing this treatment is intended to assist in addressing the physical difficulty in achieving or sustaining an erection. The desired outcome is focused on improving functional capacity within the context of sexual activity.

Quick Fact: Assists in the management of symptoms related to erectile dysfunction.

Eligibility and Restrictions for Use

Maxigra ODT is officially indicated only for adult men aged 18 years and older. The medicine is not indicated for use in women, children, or adolescents. Use in older adults requires no mandatory adjustment based on age alone, though caution applies for certain pre-existing conditions.

The medicine is contraindicated and must not be used by specific populations due to the risk of severe complications. This includes any patient concurrently taking organic nitrates or nitric oxide donors, or those taking the guanylate cyclase stimulator riociguat. It is also strictly prohibited for individuals with a known history of Non-arteritic anterior ischaemic optic neuropathy (NAION) or those with hereditary degenerative retinal disorders (e.g., retinitis pigmentosa).

Absolute contraindications also apply to patients with a recent stroke or myocardial infarction, severe hypotension (blood pressure below 90/50 mmHg), or severe hepatic impairment.

Use requires special caution in patients with severe renal impairment, conditions that predispose to priapism (like sickle cell anemia), or anatomical deformation of the penis.

What should I know about interactions with other medicines?

Maxigra ODT (sildenafil) can interact with several medicines, which may affect its safety and efficacy. It is crucial to inform your doctor or pharmacist about all prescription, over-the-counter, and herbal products you are currently taking.

ABSOLUTELY AVOID COMBINATIONS (CONTRAINDICATED)

  • Nitrates: Do not take Maxigra ODT with any form of nitrates (e.g., nitroglycerin, isosorbide mononitrate, amyl nitrite) used for chest pain or heart problems. The combination can cause a sudden, severe, and dangerous drop in blood pressure.
  • Guanylate Cyclase (GC) Stimulators: Co-administration with riociguat (Adempas) is contraindicated due to the risk of significant hypotension.

MEDICINES REQUIRING CAUTION OR DOSE ADJUSTMENT

  • CYP3A4 Inhibitors: Medicines that slow the body's breakdown of sildenafil (strong CYP3A4 inhibitors, such as ritonavir, ketoconazole, or erythromycin) can increase sildenafil levels and the risk of side effects. If taking the potent inhibitor ritonavir, the maximum sildenafil dose must not exceed 25 mg within 48 hours. A starting dose of 25 mg should be considered when co-administering with other strong CYP3A4 inhibitors.
  • Alpha-Blockers: Taking sildenafil with alpha-blockers (often prescribed for high blood pressure or prostate issues) may lead to symptomatic low blood pressure (hypotension). Sildenafil should be started at the lowest dose (25 mg) only after the patient is stable on alpha-blocker therapy.

OTHER RESTRICTIONS

The use of Maxigra ODT is not recommended in combination with other Phosphodiesterase type 5 (PDE5) inhibitors or other treatments for erectile dysfunction.

Mechanism of Action

Enzyme Inhibition and cGMP Amplification

The mechanism of Maxigra ODT is based solely on the pharmacodynamic action of its active ingredient, Sildenafil, a highly selective inhibitor of the Phosphodiesterase type 5 (PDE5) enzyme. This action directly modulates the body's vascular dynamics at the cellular level. Sildenafil functions by competitively inhibiting the PDE5 enzyme, the main biological target responsible for the breakdown of the secondary messenger cyclic Guanosine Monophosphate (cGMP) in the smooth muscle cells of the penile arteries. By blocking this enzyme, the mechanism leads to an increase and maintenance of cGMP levels within the cells, which is the necessary molecular signal for the smooth muscle to relax.

Increased Local Blood Flow

This accumulation of cGMP leads directly to vasodilation (widening) of the local blood vessels and subsequent relaxation of the surrounding smooth muscle tissue in the corpus cavernosum. This physiological change significantly increases the rate of blood inflow into the penis. Critically, this mechanism is strictly dependent on the prior release of Nitric Oxide (NO) from nerve endings, meaning the drug only potentiates the natural response to sexual arousal and remains functionally constrained without that initial signal. The resulting physiological change is mediated by Sildenafil's potentiation of the body's natural signaling process for vascular relaxation, which facilitates the physiological requirements for blood flow.

Dosage and Administration Information

How to Use Maxigra ODT — Administration Guidelines

This section outlines the general principles for the administration of sildenafil, the active component in Maxigra ODT, based on established labeling for the treatment of erectile dysfunction.

Administration Scope

Instruction Entity Statement
Route of administration The medicine is taken orally as an Orally Disintegrating Tablet (ODT).
Dosing schedule (Adults) The recommended starting dose is 50 mg, to be taken as needed. The dose may be adjusted from a minimum of 25 mg to a maximum of 100 mg.
Timing in relation to meals Administration with a high-fat meal may delay the onset of activity compared to administration on an empty stomach.
Preparation requirements The ODT formulation is designed to disintegrate quickly in the mouth without the need for water, providing an alternative method of oral administration.
Age-group administration rules A reduced starting dose of 25 mg should be considered for individuals aged 65 years or older due to altered drug clearance.
Special procedural conditions The medicine requires sexual stimulation to elicit its action. A 25 mg starting dose should also be considered for patients with severe renal or hepatic impairment and when co-administered with certain CYP3A4 inhibitors.

Instruction Classifications (High-Level)

Classification Entity Definition
Administration method type Oral.
Frequency pattern As-needed (on-demand use), strictly limited to a maximum of once per day (once every 24 hours).
Use-context constraints Dose-limiting constraints apply to specific populations and when co-administered with certain medications that affect drug concentration in the body.

The instructions establish the standard of use as an intermittent, on-demand therapy defined by a timing protocol. The dose should be administered approximately one hour prior to anticipated activity, though the label allows for intake anywhere from 30 minutes to 4 hours before. This protocol incorporates specific dose adjustments to standardize use across different patient conditions.

Recent Clinical Evidence

Maxigra ODT: Recent Clinical Evidence

The formulation of Maxigra ODT (Sildenafil Orodispersible Tablet) is primarily evaluated against the established efficacy and safety profile of the conventional sildenafil film-coated tablet (FCT).

Bioequivalence Studies

Bioequivalence studies are necessary to confirm that the Sildenafil ODT provides a similar systemic exposure of the active drug to the body compared to the established FCT, ensuring therapeutic interchangeability.

  • Studies demonstrate that sildenafil ODT, when taken without water, meets bioequivalence criteria compared to the conventional sildenafil FCT administered with water. This applies to the overall extent of drug absorption (AUC).
  • The maximum concentration of the drug in the plasma (C max) was also found to be comparable, falling within the regulatory bioequivalence limits.
  • These findings suggest that the orodispersible formulation is comparable to the original tablet in terms of how the body absorbs the active ingredient.

Clinical Outcomes and Patient Factors

Clinical trials have evaluated the effects of sildenafil across various measures relevant to its indicated use:

  • Onset of Action: The median time to the onset of erections for sildenafil 50 mg was reported in studies to be approximately 27 minutes. The ODT formulation itself is sometimes noted in studies to have a potential for a slightly faster onset, which may be meaningful for some users.
  • Patient Preference: Orodispersible tablets are studied as a more convenient route of administration, particularly for individuals who may have difficulty swallowing conventional tablets. This convenience is often associated with improved patient preference and potential for better adherence to treatment.
  • Safety Profile: The overall incidence and nature of adverse events reported in clinical trials for the ODT formulation were generally comparable to those of the conventional sildenafil tablet.

Frequently Asked Questions (FAQ)

Common questions about Maxigra ODT (FAQ)

Q: What is the usual time it takes for Maxigra ODT to start working?

A: Studies and official information indicate that Sildenafil, the active ingredient, is absorbed rapidly after administration. When taken on an empty stomach, the maximum concentration of the drug in the bloodstream is usually reached within 30 to 120 minutes, with a median time of approximately one hour. This timeframe indicates when the drug’s concentration in the body is highest.

Q: I find it hard to swallow pills. Does the ODT form of Sildenafil need to be taken with water?

A: No, the Orally Disintegrating Tablet (ODT) formulation is a specialized preparation designed to break down quickly upon contact with saliva in the mouth. This preparation is intended to be used without the need for additional liquid or water, making it a convenient alternative for oral administration.

Q: If I miss a dose of Maxigra ODT, what should I do?

A: According to the official product information, Maxigra ODT is intended only for intermittent, as-needed use before anticipated sexual activity. For this reason, there are no instructions for a 'missed dose' because the product is intended for on-demand use only.

Q: Can Maxigra ODT be used to treat Pulmonary Arterial Hypertension (PAH)?

A: Official regulatory documents confirm that Maxigra ODT is indicated only for the treatment of Erectile Dysfunction (ED) in adult men. While the active ingredient, sildenafil, is approved under a different brand name and specific dosage for treating Pulmonary Arterial Hypertension (PAH), Maxigra ODT has an indication only for Erectile Dysfunction (ED) and not for PAH.

Q: What is the correct way to dispose of my unused or expired Maxigra ODT?

A: To ensure proper pharmaceutical waste management, official guidelines state that unused or expired Maxigra ODT must not be disposed of via household waste or wastewater. It should be returned to a pharmacist or placed in an authorized drug collection program.

Q: Where does Maxigra ODT actually get metabolized in the body?

A: Official pharmacological data indicates that Sildenafil is metabolized primarily in the liver. This process involves specific liver enzymes, primarily Cytochrome P450 3A4 (CYP3A4), which is relevant to potential drug interactions.

How should Maxigra ODT be stored and disposed of?

Official Storage and Disposal Requirements

Maxigra ODT must be stored in strict accordance with the instructions provided in the official regulatory labeling to maintain its stability.

Feature Requirement from Official Labeling
Temperature Store at room temperature, typically specified as below 25 C (77 F).
Protection Keep the medicine in its original package to protect from light and moisture.
Child Safety Keep this medicine out of the sight and reach of children.
Shelf-Life Do not use after the expiry date printed on the packaging.

For disposal, unused or expired Maxigra ODT must not be thrown away via wastewater or household waste. The official procedure requires returning the product to a pharmacist or an authorized drug collection program to ensure proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSouth Korea

Equivalent of Maxigra ODT found in:

A-Z Index: